The Arthritis Therapy Acceleration Programme (A-TAP) supports the development of novel treatments for arthritis based on the underlying causes of inflammatory disease and provides a translational vehicle to “pull though” basic science discoveries into the clinic in early proof of principle experimental medicine studies along the M40 corridor. These devlopments are currently based on the internationally renounced expertise across the partnership in the Immune Mediated Inflammatory Diseases (IMIDs) of Rheumatoid Arthritis (RA), Inflammatory Bowel Disease (IBD), Sjögren’s Syndrome (SS) and Spondyloarthropathy (SpA).
One of the key objectives of the A-TAP is to provide a platform to perform Stratified Pathology: matching the right drug to the right indication early in drug discovery. We will work to develop and seek collaborations with industry partners for proof of concept and proof of mechanism with supporting biomarker studies. While there will be a focus on repurposing drugs or combination therapies we also wish to use high quality novel experimental drugs/probes to uncover new targets and pathways particularly those identified by scientists working in the Kennedy Institute .The A-TAP is not designed to replace or compete with traditional routes of funding, but rather it occupies a unique and critical niche within the translational space that will put the “A” back into Accelerated experimental studies.